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The repertoire of mutational signatures in 
human cancer
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Somatic mutations in cancer genomes are caused by multiple mutational processes, 
each of which generates a characteristic mutational signature1. Here, as part of the 
Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium2 of the International 
Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we 
characterized mutational signatures using 84,729,690 somatic mutations from 
4,645 whole-genome and 19,184 exome sequences that encompass most types of 
cancer. We identified 49 single-base-substitution, 11 doublet-base-substitution, 
4 clustered-base-substitution and 17 small insertion-and-deletion signatures. The 
substantial size of our dataset, compared with previous analyses3–15, enabled the 
discovery of new signatures, the separation of overlapping signatures and the 
decomposition of signatures into components that may represent associated—but 
distinct—DNA damage, repair and/or replication mechanisms. By estimating the 
contribution of each signature to the mutational catalogues of individual cancer 
genomes, we revealed associations of signatures to exogenous or endogenous 
exposures, as well as to defective DNA-maintenance processes. However, many 
signatures are of unknown cause. This analysis provides a systematic perspective on 
the repertoire of mutational processes that contribute to the development of human 
cancer.
Somatic mutations in cancer genomes are caused by mutational pro-
cesses of both exogenous and endogenous origin that operate dur-
ing the cell lineage between the fertilized egg and the cancer cell16. 
Each mutational process may involve components of DNA damage or 
modification, DNA repair and DNA replication (which may be normal 
or abnormal), and generates a characteristic mutational signature that 
potentially includes base substitutions, small insertions and deletions 
(indels), genome rearrangements and chromosome copy-number 
changes1. The mutations in an individual cancer genome may have 
been generated by multiple mutational processes, and thus incor-
porate multiple superimposed mutational signatures. Therefore, to 
systematically characterize the mutational processes that contribute to 
cancer, mathematical methods have previously been used to decipher 
mutational signatures from somatic mutation catalogues, estimate 
the number of mutations that are attributable to each signature in 
individual samples and annotate each mutation class in each tumour 
with the probability that it arose from each signature6,9,17–27.
Previous studies of multiple types of cancer have identified more 
than 30 single-base substitution (SBS) signatures, some of known—
but many of unknown—aetiologies, some ubiquitous and others rare, 
some part of normal cell biology and others associated with abnormal 
exposures or neoplastic progression3–5,7–15. Genome rearrangement 
signatures have also previously been described11,25,28–30. However, the 
analysis of other classes of mutation has been relatively limited3,11,31–33.
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The number of DBSs is proportional to the number of SBSs, with few exceptions
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Mutational signature analysis has predominantly used cancer exome 
sequences. However, the many-fold-greater numbers of somatic muta-
tions in whole genomes provide substantially increased power for 
signature decomposition, enabling the better separation of partially cor-
related signatures and the extraction of signatures that contribute rela-
tively small numbers of mutations. Furthermore, technical artefacts and 
differences in sequencing technologies and mutation-calling algorithms 
can themselves generate mutational signatures. Therefore, the uni-
formly processed and highly curated sets of all classes of somatic muta-
tions from the 2,780 cancer genomes of the PCAWG project2, combined 
with most other suitable cancer genomes (accession code syn11801889, 
available at https://www.synapse.org/#!Synapse:syn11801889), present 
a notable opportunity to establish the repertoire of mutational signa-
tures and determine their activities across different types of cancer. The 
timing of these signatures during the evolution of individual cancers and 
the repertoire of signatures of structural variation have been explored 
in other PCAWG analyses30,34.
Mutational signature analysis
The 23,829 samples—which include most types of cancer, and comprise 
the 2,780 PCAWG whole genomes2, 1,865 additional whole genomes and 
19,184 exomes—yielded 79,793,266 somatic SBSs, 814,191 doublet-base 
substitutions (DBSs) and 4,122,233 small indels that were analysed for 
mutational signatures, about 10-fold-more mutations than any previ-
ous study of which we are aware (syn11801889)6.
We developed classifications for each type of mutation. For SBSs, the 
primary classification comprised 96 classes (available at https://cancer.
sanger.ac.uk/cosmic/signatures/SBS) constituted by the 6 base substi-
tutions C>A, C>G, C>T, T>A, T>C and T>G (in which the mutated base is 
represented by the pyrimidine of the base pair), plus the flanking 5′ and 
3′ bases. In some analyses, two flanking bases 5′ and 3′ to the mutated 
base were considered (producing 1,536 classes) or mutations within 
transcribed genome regions were selected and classified according to 
whether the mutated pyrimidine fell on the transcribed or untranscribed 
strand (producing 192 classes). We also derived a classification for DBSs 
(78 classes; available at https://cancer.sanger.ac.uk/cosmic/signatures/
DBS). Indels were classified as deletions or insertions and—when of a single 
base—as C or T, and according to the length of the mononucleotide repeat 
tract in which they occurred. Longer indels were classified as occurring 
at repeats or with overlapping microhomology at deletion boundaries, 
and according to the size of indel, repeat and microhomology (83 classes; 
available at https://cancer.sanger.ac.uk/cosmic/signatures/ID).
The PCAWG whole-genome sequences, the additional whole-genome 
sequences and the exome sequences were each analysed separately 
(syn11801889)2. Signatures were extracted from each type of cancer 
individually, from all cancer types together, as separate SBS, DBS and 
indel signatures, and as composite signatures of all three types of muta-
tion (Supplementary Note 2).
We used two methods based on nonnegative matrix factorization 
(NMF): SigProfiler, an elaborated version of the framework used for 
the previous ‘Catalogue Of Somatic Mutations In Cancer’ (COSMIC) 
compendium of mutational signatures (COSMIC v.2, available at https://
cancer.sanger.ac.uk/cosmic/signatures_v2)11,17, and SignatureAnalyzer, 
which is based on a Bayesian variant of NMF9,27,35. NMF determines the 
signature profiles and contributions of each signature to each cancer 
genome as part of its factorization of the input matrix of mutation 
spectra. However, with many signatures and/or heterogeneous muta-
tion burdens across samples, the mutations observed in a particular 
sample can be reconstructed in multiple ways—often with small and/or 
biologically implausible contributions from many signatures. There-
fore, each method has developed a separate procedure for estimating 
the contributions of signatures to each sample (Methods).
We tested SignatureAnalyzer and SigProfiler on 11 sets of synthetic 
data (including 64,400 synthetic samples), generated from known 
signature profiles (Methods, Supplementary Note 2). Both methods 
performed well in re-extracting known signatures from realistically 
complex data. Extracted signatures that were discordant from the 
known input usually arose from difficulties in selecting the correct 
number of signatures. The results confirm that use of NMF-based 
approaches for extracting mutational signatures is not a purely algo-
rithmic process, but also requires consideration of evidence from 
experimentally determined mutational signatures and the DNA dam-
age and repair literature, prior evidence of biological plausibility and 
human-guided sensitivity analysis confirming that extractions from 
different groupings of tumours yield consistent results. We used these 
types of evidence and approaches in determining the signature pro-
files reported here. The findings are consistent with results regard-
ing NMF, and the related areas of probabilistic topic modelling and 
latent Dirichlet allocation, in multiple problem domains36,37. It is widely 
understood that the choice of the number of latent variables (for our 
purposes, the number of mutational signatures) is rarely amenable to 
complete automation.
The results from our SigProfiler and SignatureAnalyzer analyses 
of cancer data exhibited many similarities, and we assigned the same 
identifiers to similar signatures extracted using the two methods 
(syn12016215). However, there were also noteworthy differences. 
The numbers of SBS signatures found in PCAWG tumours with a low 
mutation burden (94.4% of cases that contain 47% of mutations) were 
similar: 31 using SigProfiler and 35 using SignatureAnalyzer. However, 
the numbers of additional SBS signatures extracted from hypermutated 
PCAWG samples (5.6% of cases, containing 53% of mutations) were dif-
ferent: 13 using SigProfiler and 25 using SignatureAnalyzer. There were 
also differences in SBS signature profiles, including among signatures 
found in cases with a low mutation burden. The latter primarily involved 
relatively featureless (‘flat’) signatures, which are mathematically chal-
lenging to deconvolute. Finally, there were differences in signature 
attributions to individual samples. SignatureAnalyzer used more sig-
natures to reconstruct the mutational profiles (Extended Data Fig. 1) 
(syn12169204 and syn12177011) and attributions to flat signatures were 
different (Extended Data Fig. 2a, b) (syn12169204). The DBS and indel 
signatures were generally similar between the two methods (Extended 
Data Fig. 2c, d).
The final reference mutational signatures were determined from 
the PCAWG set, supplemented by additional signatures from the other 
datasets (COSMIC, available at https://cancer.sanger.ac.uk/cosmic/
signatures). Each signature was allocated an identifier consistent with, 
and extending, the COSMIC v.2 annotation. Some previous signatures 
split into multiple constituent signatures: these were numbered as in 
the previous annotation, but with additional letter suffixes (for exam-
ple, SBS17 was split into SBS17a and SBS17b). DNA sequencing and 
analysis artefacts also generate mutational signatures. We indicate 
which signatures are possible artefacts but do not present them below 
(full information is available at https://cancer.sanger.ac.uk/cosmic/
signatures). The results of both SignatureAnalyzer and SigProfiler were 
used throughout the study. However, for brevity and for continuity 
with the signature set previously displayed in COSMIC v.2—which has 
been widely used as a reference—SigProfiler results are outlined here, 
and SignatureAnalyzer results are provided in Extended Data Figs. 3, 
4 and at syn11738307.
Single-base substitution signatures
There were substantial differences in the numbers of SBSs between 
samples (ranging from hundreds to millions) and between cancer 
types38 (Fig. 1). In total, 67 SBS mutational signatures were extracted, 
of which 49 were considered likely to be of biological origin (Fig. 2, 
Methods; available at https://cancer.sanger.ac.uk/cosmic/signatures/
SBS/). Except for signature SBS25, all signatures reported in COSMIC v.2 
(ref. 6) were confirmed; the median cosine similarity between the newly 
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derived signatures and those on COSMIC v.2 was 0.95, excluding the 
‘split’ signatures (discussed below). SBS25 was previously found in cell 
lines derived from Hodgkin lymphomas treated with chemotherapy, 
and no primary cancers of this type were available. The newly derived 
signatures showed much improved separation from each other and 
more-distinct signature profiles, as compared with COSMIC v.2 sig-
natures (see ‘Better separation compared to COSMIC v.2 signatures’ 
in Supplementary Note 2 for more information).
Thirteen of the SBS signatures we extracted (excluding those due 
to signature splitting) represent newly identified and probably real 
signatures, not present in COSMIC v.2. Some were rare (SBS31, SBS32, 
SBS35, SBS36, SBS42 and SBS44). Others were more common, but con-
tributed relatively few mutations and/or were similar to previously 
discovered signatures (SBS38, SBS39 and SBS40). Notably, SBS40 is a 
flat signature similar to SBS5. It contributes to multiple types of can-
cer, but its similarity to SBS5 renders the extent of this contribution 
uncertain. For some of the newly identified signatures, there were 
plausible underlying aetiologies (Fig. 3, Extended Data Figs. 4, 5): for 
SBS31 and SBS35, platinum compound chemotherapy39; for SBS32, 
azathioprine therapy; for SBS36, inactivating germline or somatic 
mutations in MUTYH (which encodes a component of the base excision 
repair machinery)40,41; for SBS38, additional effects of exposure to ultra-
violet (UV) light; for SBS42, occupational exposure to haloalkanes13; 
and for SBS44, defective DNA mismatch repair42.
Three previously characterized base substitution signatures (SBS7, 
SBS10 and SBS17) split into multiple constituent signatures (Fig. 2). 
Signature splitting probably reflects the existence of multiple distinct 
mutational processes initiated by the same exposure that have closely—
but not perfectly—correlated activities. We previously regarded SBS7 
as a single signature composed predominantly of C>T at CCN and TCN 
trinucleotides (the mutated base is underlined) together with many 
fewer T>N mutations. It was found in malignant melanomas and squa-
mous skin carcinomas, and is probably due to the UV-light-induced 
formation of pyrimidine dimers, followed by translesion DNA synthesis 
by error-prone polymerases predominantly inserting A opposite to 
damaged cytosines. SBS7 has now been decomposed into four con-
stituent signatures. SBS7a and SBS7b (consisting mainly of C>T at TCN 
and C>T at CCN, respectively) may reflect different pyrimidine-dimer 
photoproducts. SBS7c and SBS7d (consisting predominantly of T>A 
at NTT and T>C at NTT, respectively43) may be due to low frequencies 
of the misincorporation of T and G opposite to thymines in pyrimidine 
dimers. The splitting of SBS10 and SBS17 is described at https://cancer.
sanger.ac.uk/cosmic/signatures/SBS/.
Several base substitution signatures showed transcriptional strand 
bias, which may be attributable to transcription-coupled nucleotide 
excision repair acting on DNA damage and/or to an excess of DNA dam-
age on untranscribed strands of genes44. Both mechanisms result in 
more mutations of damaged bases on untranscribed than on tran-
scribed strands of genes. Assuming that either mechanism is respon-
sible for the observed transcriptional strand biases, DNA damage to 
cytosine (SBS7a and SBS7b), guanine (SBS4, SBS8, SBS19, SBS23, SBS24, 
SBS31, SBS32, SBS35 and SBS42), thymine (SBS7c, SBS7d, SBS21, SBS26 
and SBS33) and adenine (SBS5, SBS12, SBS16, SBS22 and SBS25) may 
underlie these mutational signatures (plots of strand bias are available 
at https://cancer.sanger.ac.uk/cosmic/signatures/SBS/). The likely 
DNA-damaging agents are known for SBS4 (tobacco mutagens), SBS7a, 
SBS7b, SBS7c and SBS7d (UV light), SBS22 (aristolochic acid), SBS24 
(aflatoxin), SBS25 (chemotherapy), SBS31 and SBS35 (platinum com-
pounds), SBS32 (azathioprine) and SBS42 (haloalkanes).
Using the SBS classification of 1,536 mutation types, which uses the 
sequence context two bases 5′ and two bases 3′ to each mutated base, 
yielded signatures that are largely consistent with those based on sub-
stitutions in trinucleotide contexts. Notably, however, two forms of 
both SBS2 and SBS13 were extracted, one with mainly a pyrimidine and 
the other with mainly a purine at the −2 base (the second base 5′ to the 
mutated cytosine). These may represent the activities of the cytidine 
deaminases APOBEC3A and APOBEC3B, respectively45. If so, APOBEC3A 
accounts for many more mutations than APOBEC3B in cancers with 
high APOBEC activity. Other signatures showed nonrandom sequence 
contexts at +2 and −2 positions (for example, SBS17a, SBS17b and SBS9), 
but sequence context effects were generally much stronger for bases 
immediately 5′ and 3′ to mutated bases.
SBS signatures showed substantial variation in the numbers of can-
cer types and cancer samples in which they were found, and in the 
mutations attributed per cancer sample (Fig. 3). Almost all individual 
cancer samples exhibited multiple signatures, with a mode of three in 
log10(mutations per megabase)
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the PCAWG set (syn12169204). The assigned signatures reconstruct 
well the mutational spectra of the cancer samples (in PCAWG samples, 
the median cosine similarity was 0.97; 96.3% of samples with cosine 
similarity >0.90): Fig. 4 shows illustrative examples.
Some mutational processes generate base substitutions that cluster 
in small genomic regions. The limited numbers of such mutations may 
result in a failure to detect their signatures using standard methods. We 
therefore identified clustered mutations in each genome and analysed 
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Fig. 2 | Profiles of SBS, DBS and small indel mutational signatures. The 
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smoking) are shown to illustrate the positions of each mutation subtype on 
each plot. The plotted data are available in digital form (along with the x axis 
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them separately (Methods). Four main clustered mutational signatures 
were identified (Fig. 2), as previously reported4,27,32. Two, which are found 
in multiple types of cancer, were similar to SBS2 and SBS13 (which have 
been attributed to APOBEC enzyme activity) and represent foci of katae-
gis3,32,46. Two further clustered signatures, one characterized by C>T and 
C>G mutations at (A or G)C(C or T) trinucleotides47 and the other T>A 
and T>C mutations at (A or T)T(A or T), were found in lymphoid neo-
plasms; they probably represent the direct and indirect consequences of 
activation-induced cytidine deaminase mutagenesis and translesion DNA 
synthesis by error-prone polymerases (SBS84 and SBS85, respectively)27.
Doublet-base substitution signatures
Tandem doublet, triplet, quadruplet, quintuplet and sextuplet base 
substitutions (syn11801938 and syn11726620) were observed at about 
1% the prevalence of SBSs. In most cancer genomes, the number of DBSs 
was considerably higher than would be expected from the random 
adjacency of SBSs (syn12177057), indicating the existence of com-
monly occurring, single mutagenic events that cause substitutions 
at neighbouring bases. There was substantial variation in the number 
of DBSs, ranging from 0 to 20,818 in a sample. The numbers of DBSs 
were generally proportional to the numbers of SBSs (Fig. 1), although 
colorectal adenocarcinomas had fewer than expected, and lung cancers 
and melanomas had more (Extended Data Table 1). We extracted eleven 
DBS signatures (Fig. 2, of which three have previously been reported33,48.
Signature DBS1 was characterized by CC>TT mutations (Fig. 2), con-
tributed hundreds to tens of thousands of mutations in malignant mela-
nomas with SBS7a and SBS7b (Fig. 3), exhibited transcriptional strand 
bias consistent with damage to cytosines (syn12177063) and is a known 
consequence of DNA damage induced by UV light33,49. Excluding cancers 
associated with exposure to UV light also yielded a signature (DBS11) 
that was characterized predominantly by CC>TT mutations, but only 
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Fig. 3 | The number of mutations contributed 
by each mutational signature to the PCAWG 
tumours. The size of each dot represents the 
proportion of samples of each tumour type that 
shows the mutational signature. The colour of 
each dot represents the median mutation 
burden of the signature in samples that show the 
signature. Tumours that had few mutations or 
that were poorly reconstructed by the 
signature assignment were excluded. The 
contributions of composite signatures to the 
PCAWG cancers, and SBS signatures to the 
complete set of cancer samples analysed, are 
shown in Extended Data Figs. 4 and 5, 
respectively. AML, acute myeloid leukaemia; 
liposarc, liposarcoma; MDS, myelodysplastic 
syndrome.
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contributing tens of mutations in many samples from multiple types 
of cancer (Figs. 2, 3). DBS11 was associated with SBS2, which is due to 
APOBEC activity: APOBEC activity may, therefore, also generate DBS11.
DBS2 was composed predominantly of CC>AA mutations, with 
smaller numbers of CC>AG and CC>AT mutations, and contributed 
hundreds to thousands of mutations in lung adenocarcinoma, lung 
squamous and head and neck squamous carcinomas, which are often 
caused by tobacco smoking33 (Figs. 2, 3). DBS2 showed transcriptional 
strand bias indicative of guanine damage (syn12177064) and was asso-
ciated with SBS4, which is caused by exposure to tobacco smoke. It is 
likely, therefore, that DBS2 can be a consequence of DNA damage by 
tobacco-smoke mutagens.
A signature similar to DBS2 contributed hundreds of mutations to 
liver cancers and tens of mutations to other types of cancer without 
evidence of exposure to tobacco smoke. A pattern resembling DBS2 
also dominates DBSs in healthy mouse cells50. The nature of the muta-
tional processes that underlie these signatures in human cancers that 
are unrelated to smoking, and in healthy mice, is unknown. However, in 
experimental systems, acetaldehyde exposure has been shown to gen-
erate a mutational signature characterized primarily by CC>AA muta-
tions, and lower burdens of CC>AG and CC>AT mutations, together 
with C>A SBSs48. Acetaldehyde is an oxidation product of alcohol and a 
constituent of cigarette smoke. The role of acetaldehyde, and perhaps 
other aldehydes, in generating DBS2 merits further investigation51.
DBS3, DBS7, DBS8 and DBS10 showed hundreds to thousands of muta-
tions in rare colorectal, stomach and oesophageal cancers, some of which 
showed evidence of defective DNA mismatch repair (DBS7 and DBS10) or 
polymerase epsilon exonuclease domain mutations (DBS3) that generate 
hypermutator phenotypes (Figs. 2, 3). DBS5 was found in cancers exposed 
to platinum chemotherapy, and is associated with SBS31 and SBS35.
Small insertion-and-deletion signatures
Indels were usually present at about 10% of the frequency of base 
substitutions (Fig. 1). There was substantial variation between cancer 
genomes in the number of indels, even when cancers with evidence of 
defective DNA mismatch repair were excluded. Overall, the numbers of 
deletions and insertions were similar, but there was variation between 
cancer types: some cancers showed more deletions and others more 
insertions of various subtypes (Fig. 1). We extracted 17 indel mutational 
signatures (Fig. 2).
Indel signature 1 (ID1) was composed predominantly of insertions of 
thymine and ID2 was composed predominantly of deletions of thymine, 
both at long (≥5) thymine mononucleotide repeats (Fig. 2). Tens to 
hundreds of mutations of both signatures were found in most samples 
of most types of cancer, but were particularly common in colorectal, 
stomach, endometrial and oesophageal cancers and in diffuse large B 
cell lymphoma (Fig. 3). Together, ID1 and ID2 accounted for 97% and 
45% of indels in hypermutated and non-hypermutated cancer genomes, 
respectively (Extended Data Table 2). They are probably due to slip-
page of either the nascent (ID1) or template strand (ID2) during DNA 
replication of long mononucleotide tracts.
ID3 was characterized predominantly by deletions of cytosine at 
short (≤5-bp long) mononucleotide cytosine repeats and exhibited 
hundreds of mutations in cancers of the lung, head and neck that are 
associated with tobacco smoking (Figs. 2, 3). There was transcriptional 
strand bias of mutations, with more guanine deletions than cytosine 
deletions on the untranscribed strands of genes, which is compatible 
with transcription-coupled nucleotide excision repair of damaged 
guanine (syn12177065 and syn12177066). The numbers of ID3 mutations 
positively correlated with the numbers of SBS4 and DBS2 mutations, 
which we have shown are associated with tobacco smoking (Extended 
Data Figs. 6, 7). Thus, DNA damage by components of tobacco smoke 
probably underlie ID3.
ID13 was characterized predominantly by deletions of thymine at 
thymine–thymine dinucleotides and exhibited large numbers of muta-
tions in malignant melanomas of the skin (Figs. 2, 3). The numbers 
of ID13 mutations correlated with the numbers of SBS7a, SBS7b and 
DBS1 mutations, which we have attributed to DNA damage induced 
by UV light (Extended Data Figs. 6, 7). However, deletions of cytosine 
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at cytosine–cytosine dinucleotides did not feature strongly in ID13, 
which may reflect the predominance of thymine compared to cytosine 
dimers induced by UV light52.
ID6 and ID8 were both characterized predominantly by ≥5-bp dele-
tions (Fig. 2). ID6 exhibited overlapping microhomology at deletion 
boundaries with a mode of 2 bp (and often longer stretches) and cor-
related with SBS3, which we have attributed to defective homologous-
recombination-based repair (Extended Data Figs. 6, 7). By contrast, ID8 
deletions showed shorter or no microhomology at deletion boundaries 
and did not strongly correlate with SBS3. Both deletion patterns may be 
characteristic of DNA double-strand-break repair by non-homologous-
recombination-based end-joining mechanisms and—if so—this suggests 
that at least two distinct forms are operative in human cancer53.
A small fraction of cancers exhibited very large numbers of ID1 and 
ID2 mutations (>10,000) (Fig. 3) (shown at https://cancer.sanger.ac.uk/
cosmic/signatures/ID). These were usually accompanied by SBS6, 
SBS14, SBS15, SBS20, SBS21, SBS26 and/or SBS44, which are associated 
with deficiency in DNA mismatch repair—sometimes combined with 
POLE or POLD1 proofreading deficiency (SBS14 and SBS20)35. Occa-
sional cases with these signatures additionally showed large numbers 
of indels attributed to ID7 (syn11738668), and rare samples showed 
large numbers of ID4, ID11, ID14, ID15, ID16 or ID17 mutations but did 
not show large numbers of ID1 and ID2 mutations or the SBS signatures 
associated with deficiency in DNA mismatch repair.
Correlations with age
A positive correlation between age of cancer diagnosis and the number 
of mutations attributable to a signature suggests that the underlying 
mutational process has been operative (at a more or less constant rate) 
throughout the cell lineage from fertilized egg to cancer cell, and thus in 
the normal cells from which that type of cancer develops6,54. Confirming 
previous reports6,54, the numbers of SBS1 and SBS5 mutations correlate 
with age, and exhibit different rates in different types of tissue (q val-
ues provided in syn12030687, syn20317940 and syn12217988). SBS40 
also correlated with age in multiple types of cancer, although—given 
its similarity to SBS5—misattribution cannot be excluded. DBS2 and 
DBS4 correlated with age; consistent with activity in normal cells and, 
when combined their profiles closely resemble the spectrum of DBS 
mutations found in normal mouse cells50. ID1, ID2, ID5 and ID8 showed 
correlations with age in multiple tissues. ID1 and ID2 indels are probably 
due to slippage at poly T repeats during DNA replication and correlated 
with the numbers of SBS1 substitutions, which have previously been 
proposed to reflect the number of mitoses a cell has experienced6. 
Thus, SBS1, ID1 and ID2 may all be generated during DNA replication 
at mitosis. The number of ID5 mutations correlated with the number 
of SBS40 mutations, and the mutational processes that underlie these 
two age-correlated signatures may therefore contain common compo-
nents. ID8, which is predominantly composed of ≥5-bp deletions with 
no or 1 bp of microhomology at their boundaries, is probably due to 
DNA double-strand breaks repaired by a non-homologous-end-joining 
mechanism. The results indicate that multiple mutational processes 
operate in normal cells.
Discussion
There are important constraints, limitations and assumptions in the 
analytic frameworks used here to characterize mutational signatures. 
Signatures extracted from sample sets in which multiple processes 
are operative remain mathematical approximations, with profiles 
that are potentially influenced by the mathematical approach used 
and other factors. For conceptual and practical simplicity, we assume 
that a single signature is associated with each mutational process and 
provide an average reference signature to represent it. However, we 
do not discount the possibility that further nuances and variations 
of signature profiles exist. We have estimated the contributions from 
each signature to the mutation burden in each sample. However, with 
increasing numbers of signatures and differences of multiple orders 
of magnitude in mutation burdens between some signatures, prior 
knowledge has helped to avoid biologically implausible results. Thus, 
the further development of methods for deciphering and attributing 
mutational signatures is warranted, ideally supported by signatures 
derived from experimental systems in which the causes are known. 
Nevertheless, signatures with many similarities and some differences 
can be found by different mathematical approaches, and these can 
be confirmed in several ways, including experimentally elucidated 
signatures5,31,39,42,43,54–62 and tumours dominated by a single signature 
(syn12016215).
This analysis includes most publicly available exome and whole-
genome cancer sequences. Some rare or geographically restricted 
signatures may not have been captured, signatures conferring limited 
mutation burdens may have been missed and signatures of therapeutic 
mutagenic exposures have not been exhaustively explored. Neverthe-
less, it is likely that a substantial proportion of the naturally occurring 
mutational signatures found in human cancer have now been described. 
This comprehensive repertoire provides a foundation for research into 
the aetiologies of geographical and temporal differences in cancer 
incidence, the mutational processes that operate in healthy tissues 
and non-neoplastic disease states, clinical and public health applica-
tions of signatures and mechanistic understanding of the mutational 
processes that underlie carcinogenesis.
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Methods
No statistical methods were used to predetermine sample size. The 
experiments were not randomized and investigators were not blinded 
to allocation during experiments and outcome assessment.
These online methods contain an abridged description of the meth-
odology used in the current manuscript; extensive details about the 
methodology we used are provided in Supplementary Note 2. Impor-
tantly, two independently developed computational frameworks (Sig-
Profiler and SignatureAnalyzer) based on NMF were applied separately 
to the examined sets of mutational catalogues. SigProfiler and Signa-
tureAnalyzer take different approaches for deciphering mutational 
signatures and for assigning each signature to each sample. By using 
two methods, we aimed to provide a perspective on the effect that dif-
ferent methodologies can have on the numbers of signatures generated, 
signature profiles and attributions. In addition to applying SigProfiler 
and SignatureAnalyzer to cancer data, the tools were also applied to 
realistic synthetic data with known solutions.
Analysis of mutational signatures with SigProfiler
SigProfiler incorporates two distinct steps for identification of muta-
tional signatures, based on the previously described methodology6,11,17 
(Extended Data Fig. 8). The first step (SigProfilerExtraction) encom-
passes a hierarchical de novo extraction of mutational signatures based 
on somatic mutations and their immediate sequence context, and the 
second step (SigProfilerAttribution) focuses on accurately estimating 
the number of somatic mutations associated with each extracted muta-
tional signature in each sample. SigProfilerExtraction is an extension 
of a previous framework for the analysis of mutational signatures11,17. In 
brief, for a given set of mutational catalogues, the algorithm deciphers 
a minimal set of mutational signatures that optimally explains the 
proportion of each mutation type and estimates the contribution of 
each signature to each sample. More specifically, for each NMF itera-
tion, SigProfilerExtraction minimizes a generalized Kullback–Leibler 
divergence constrained for nonnegativity (Supplementary Note 2). The 
algorithm uses multiple NMF iterations (in most cases 1,024) to identify 
the matrix of mutational signatures and the matrix of the activities of 
these signatures, as previously described17. The unknown number of 
signatures is determined by human assessment of the stability and 
accuracy of solutions for a range of values, as previously described17. 
The framework is applied hierarchically to increase its ability to find 
mutational signatures that generate few mutations or are present in 
few samples.
After signatures are discovered by SigProfilerExtraction, SigPro-
filerAttribution estimates their contributions to individual samples. 
For each examined sample, the estimation algorithm involves finding 
the minimum of the Frobenius norm of a constrained function using a 
nonlinear convex optimization programming solver using the interior-
point algorithm63. See Supplementary Note 2 and Extended Data Fig. 
8b for further details.
Analysis of mutational signatures with SignatureAnalyzer
SignatureAnalyzer uses a Bayesian variant of NMF that infers the num-
ber of signatures through the automatic relevance determination tech-
nique and delivers highly interpretable and sparse representations for 
both signature profiles and attributions that strike a balance between 
data fitting and model complexity. Further details of the actual imple-
mentation of the computational approach have previously been pub-
lished9,27,64. SignatureAnalyzer was applied by using a two-step signature 
extraction strategy using 1,536 pentanucleotide contexts for SBSs, 83 
indel features and 78 DBS features. In addition to the separate extrac-
tion of SBS, indel and DBS signatures, we performed a ‘COMPOSITE’ 
signature extraction based on all 1,697 features (1,536 SBS + 78 DBS + 
83 indel). For SBSs, the 1,536 SBS COMPOSITE signatures are preferred; 
for DBSs and indels, the separately extracted signatures are preferred.
In step 1 of the two-step extraction process, global signature extrac-
tion was performed for the samples with a low mutation burden 
(n = 2,624). These excluded hypermutated tumours: those with puta-
tive polymerase epsilon (POLE) defects or mismatch repair defects 
(microsatellite instable tumours), skin tumours (which had intense 
UV-light mutagenesis) and one tumour with temozolomide (TMZ) 
exposure. Because the underlying algorithm of SignatureAnalyzer 
performs a stochastic search, different runs can produce different 
results. In step 1, we ran SignatureAnalyzer 10 times and selected the 
solution with the highest posterior probability. In step 2, additional 
signatures unique to hypermutated samples were extracted (again 
selecting the highest posterior probability over ten runs) while allow-
ing all signatures found in the samples with low mutation burden, to 
explain some of the spectra of hypermutated samples. This approach 
was designed to minimize a well-known ‘signature bleeding’ effect or a 
bias of hyper- or ultramutated samples on the signature extraction. In 
addition, this approach provided information about which signatures 
are unique to the hypermutated samples, which was later used when 
attributing signatures to samples.
A similar strategy was used for signature attribution: we performed a 
separate attribution process for low- and hypermutated samples in all 
COMPOSITE, SBS, DBS and indel signatures. For downstream analyses, 
we preferred to use the COMPOSITE attributions for SBSs and the sepa-
rately calculated attributions for DBSs and indels. Signature attribu-
tion in samples with a low mutation burden was performed separately 
in each tumour type (for example, Biliary–AdenoCA, Bladder–TCC, 
Bone–Osteosarc, and so on). Attribution was also performed separately 
in the combined microsatellite instable tumours (n = 39), POLE (n = 9), 
skin melanoma (n = 107) and TMZ-exposed samples (syn11738314). In 
both groups, signature availability (which signatures were active, or 
not) was primarily inferred through the automatic relevance determi-
nation process applied to the activity matrix H only, while fixing the 
signature matrix W. The attribution in samples with a low mutation 
burden was performed using only signatures found in the step 1 of the 
signature extraction. Two additional rules were applied in SBS signature 
attribution to enforce biological plausibility and minimize a signature 
bleeding: (i) allow SBS4 (smoking signature) only in lung, head and neck 
cases; and (ii) allow SBS11 (TMZ signature) in a single GBM sample. This 
was enforced by introducing a binary, signature-by-sample signature 
indicator matrix Z (1, allowed; 0, not allowed), which was multiplied by 
the H matrix in every multiplication update of H. No additional rules 
were applied to indel or DBS signature attributions, except that sig-
natures found in hypermutated samples were not allowed in samples 
with a low mutation burden.
Application of SigProfiler and SignatureAnalyzer to synthetic 
data
Our goal was to evaluate SignatureAnalyzer and SigProfiler on real-
istic synthetic data to identify any potential limitations of these two 
methods. SignatureAnalyzer and SigProfiler were tested on 11 sets of 
synthetic data, encompassing a total of 64,400 synthetic samples, in 
which known signature profiles were used to generate catalogues of 
synthetic mutational spectra. We operationally defined ‘realistic’ data 
as those based on the characteristics of either SignatureAnalyzer’s or 
SigProfiler’s analysis of the PCAWG genome data. SignatureAnalyzer’s 
reference signature profiles were based on COMPOSITE signatures, 
consisting of 1,536 types of strand-agnostic SBSs in pentanucleotide 
context, 78 types of DBSs and 83 types of small indels, for a total of 
1,697 mutation types. SigProfiler’s reference analysis was based on 
strand-agnostic SBSs in the context of one 5′ and one 3′ base. For each 
test, we generated two sets of realistic data: SigProfiler-realistic (based 
on SigProfiler’s reference signatures and attributions) and Signature-
Analyzer-realistic (based on SignatureAnalyzer’s reference signatures 
and attributions), as well as two other types of data that involved using 
SignatureAnalyzer profiles with SigProfiler attributions and vice versa. 
A detailed description of each of the 11 sets of synthetic data and the 
results from applying SigProfiler and SignatureAnalyzer are provided 
in Supplementary Note 2.
Analysis of clustered mutational signatures
Somatic SBSs were considered clustered if they had intermutational 
distances < 1,000 bp. More specifically, for each sample, an SBS muta-
tional catalogue was generated for substitutions that were <1,000 bp 
from another substitution. Subsequently, the set of SBS mutational 
catalogues containing clustered mutations underwent de novo extrac-
tion of mutational signatures. Any novel mutational signature (one 
that was not previously observed in the complete SBS catalogues) was 
reported as a clustered mutational signature.
Better separation compared to COSMIC v.2 signatures
As described in the manuscript, all mutational signatures previously 
reported in COSMIC v.2 were confirmed in the new set of analyses with 
median cosine similarity of 0.95. However, the separation between 
the COSMIC v.2 mutational signatures (https://cancer.sanger.ac.uk/
cosmic/signatures_v2) is much worse than the separation between 
the mutational signatures reported here. For example, in COSMIC v.2, 
signatures 5 and 16 had a cosine similarity of 0.90, making them hard 
to distinguish from one another. By contrast, in the current analysis, 
SBS5 and SBS16 have a cosine similarity of 0.65. This allows us to unam-
biguously assign SBS5 and SBS16 to different samples. In the current 
analysis, the larger number of samples has allowed the reduction of 
bleeding between signatures and has given more unique and easily 
distinguishable signatures. One can evaluate the overall separation of 
a set of mutational signatures by examining the distribution of cosine 
similarities between the signatures in the set. The signatures in COS-
MIC v.2 had a median cosine similarity of 0.238. By contrast, the current 
signatures have a much lower median cosine similarity of 0.098. This 
twofold reduction in similarity is highly statistically significant (P value 
9.1 × 10−25) and indicates a better separation between the signatures in 
the current analysis.
Correlations of mutational signature activity with age
Before evaluating the association between age and the activity of a 
mutational signature, all outliers for both age and numbers of muta-
tions attributed to a signature in a cancer type were removed from 
the data. An outlier was defined as any value outside three standard 
deviations from the mean value. A robust linear regression model that 
estimated the slope of the line and whether this slope was significantly 
different from zero (F test; P value < 0.05) was performed using the 
MATLAB function robustfit (https://www.mathworks.com/help/stats/
robustfit.html) with default parameters. The P values from the F tests 
were corrected using the Benjamini–Hochberg procedure for false 
discovery rates. Results are available at syn12030687 and syn20317940.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Somatic and germline variant calls, mutational signatures, sub-
clonal reconstructions, transcript abundance, splice calls and other 
core data generated by the ICGC and TCGA PCAWG Consortium are 
described in ref. 2, and are available for download at https://dcc.icgc.
org/releases/PCAWG. Additional information on accessing the data, 
including raw read files, can be found at https://docs.icgc.org/pcawg/
data/. In accordance with the data access policies of the ICGC and TCGA 
projects, most molecular, clinical and specimen data are in an open 
tier that does not require access approval. To access information that 
could potentially identify participants, such as germline alleles and 
the underlying sequencing data, researchers will need to apply to the 
TCGA data access committee via dbGaP (https://dbgap.ncbi.nlm.nih.
gov/aa/wga.cgi?page=login) for access to the TCGA portion of the 
dataset, and to the ICGC data access compliance office (http://icgc.org/
daco) for the ICGC portion of the dataset. In addition, to access somatic 
single nucleotide variants derived from TCGA donors, researchers 
will also need to obtain dbGaP authorization. For each mutational 
signature as extracted by SigProfiler, there is a ‘vignette’ that con-
sists of plots and a short textual description at COSMIC (available at 
https://cancer.sanger.ac.uk/cosmic/signatures/). Beyond the core 
sequence data generated by the ICGC and TCGA PCAWG Consortium, 
other derived datasets were generated by the research reported in this 
paper. These derived datasets are available at Synapse (https://www.
synapse.org/#!Synapse:syn11726601/wiki/513478), and are denoted by 
accession numbers (synXXXXXXXX). All these datasets are mirrored 
at https://dcc.icgc.org/releases/PCAWG/mutational_signatures/ with 
full links, filenames, accession numbers and descriptions as detailed in 
Supplementary Table 1. These datasets include (1) CSV files comprising 
all catalogues of observed mutational spectra that were used as input 
to signature extraction (syn11801889), (2) CSV files and plots of signa-
tures extracted by SigProfiler (syn11738306) and SignatureAnalyzer 
(syn11738307), (3) CSV files with estimates of the numbers of mutations 
generated by each signature in individual tumours (syn11804065), (4) 
estimates of the probability that each signature was responsible for 
each mutational type (for example, CTG>CAG) in individual tumours 
(syn11804068) and (5) synthetic test input data plus the results of 
tests of signature extraction (discovery) on the synthetic test data 
(syn18497223). All derived datasets are open access, and can be down-
loaded without registration or logging in.
Code availability
SigProfiler is available both as a MATLAB framework and as a Python 
package. In both cases, SigProfiler is a fully functional, free and open-
source tool distributed under the permissive 2-Clause BSD License. 
SigProfiler in MATLAB can be downloaded from: https://www.math-
works.com/matlabcentral/fileexchange/38724-sigprofiler. SigProfiler 
in Python can be downloaded from: https://github.com/Alexandrov-
Lab/SigProfilerExtractor. SignatureAnalyzer code is available at https://
github.com/broadinstitute/getzlab-SignatureAnalyzer (github.com). 
The code used to generate the synthetic data and summarize Signatu-
reAnalyzer and SigProfiler results is open source and freely available as 
the SynSig package: https://github.com/steverozen/SynSig/tree/v0.2.0 
under the GNU General Public License v.3.0. The core computational 
pipelines used by the PCAWG Consortium for alignment, quality control 
and variant calling are available to the public at https://dockstore.org/
search?search=pcawg under the GNU General Public License v.3.0, 
which allows for reuse and distribution.
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Extended Data Fig. 1 | Histogram of the number of signatures attributed in each of 2,780 PCAWG samples by SigProfiler and SignatureAnalyzer. 
Hypermutated tumours and melanomas (156) are listed at syn11738314.
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Extended Data Fig. 2 | Comparisons between results of SigProfiler and 
SignatureAnalyzer. a, b, Comparison of the attributions for corresponding 
SigProfiler (a) and SignatureAnalyzer (b) signatures. Each one of the SBS 
signatures extracted by SigProfiler and SignatureAnalyzer was paired with the 
signature of highest cosine similarity in the extraction by the other method (if 
one with >0.85 cosine similarity exists). The first column of the plot 
corresponds to the fraction of mutations assigned by one method (summed 
across samples and mutation types) that was also assigned by the other 
method. The remaining mutations were then redistributed to the other 
signatures in the extraction, weighted by their relative probabilities of having 
been generated by each signature and the resulting fraction of mutations was 
then plotted. Signatures on the x axis are shown only if they contribute at least a 
0.1 fraction of mutations to at least one signature on the y axis. c, d, Cosine 
similarities between SigProfiler and SignatureAnalyzer DBS (c) and indel (d) 
signatures. Brown nodes represent SigProfiler signatures; green nodes 
represent SignatureAnalyzer signatures. Matches with cosine 
similarities > 0.8 are shown as edges; the width of the edge indicates the 
strength of the similarity. The locations of the nodes have no meaning. 
Signatures with no matches of >0.8 cosine similarity are shown below. 
SigProfiler ID15 and ID17 were extracted from data that were not analysed by 
SignatureAnalyzer. The suffix ‘P’ on a SignatureAnalyzer signature name 
indicates a signature extracted from non-hypermutated, non-melanoma 
tumours. The suffix ‘S’ on a SignatureAnalyzer signature name indicates a 
signature extracted from hypermutated or melanoma tumours.
Extended Data Fig. 3 | SignatureAnalyzer reference signatures. The classifications of each mutation type (SBS, 96 classes; DBS, 78 classes; and indels, 
83 classes) are described in the main text.
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Extended Data Fig. 4 | The number of SBS mutations attributed to each mutational signature for each cancer type over the PCAWG tumours by 
SignatureAnalyzer. Conventions are as in Fig. 3; see this figure for explanation.
Extended Data Fig. 5 | The number of SBS mutations attributed to each mutational signature to each cancer type over the complete set of PCAWG and non-
PCAWG cancer samples analysed by SigProfiler. Conventions are as in Fig. 3; see this figure for explanation.
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Extended Data Fig. 6 | Associations between SBS, DBS and indel signature 
activities for SigProfiler and SignatureAnalyzer. a, b, Each node represents 
an SBS (light green), DBS (dark green) or indel (black) signature. Any two 
signatures with sample attributions that significantly correlated with R2 > 0.3 
(SigProfiler) (a) or > 0.5 (SignatureAnalyzer) (b) are connected by edges. Edge 
widths are proportional to the strength of the correlation. Signatures with no 
significant correlation to any other signature above the relevant threshold are 
not shown. Signature locations are fit for display purposes only, and do not 
indicate similarity.
Extended Data Fig. 7 | Mutational signatures extracted from the 
COMPOSITE feature set consisting of the concatenation of SBSs in 
pentanucleotide context, DBSs and indels. For each of the 4 COMPOSITE 
mutational signatures shown, the top panel shows the SBS signature in 
pentanucleotide context (1,536 mutation classes) after being collapsed to 
96 SBS mutation classes, the middle panel is the co-extracted DBS signature 
and the bottom panel is the co-extracted indel signature. There are similarities 
between the DBS portion of Composite-4 and DBS2, and between the indel 
portion of Composite-4 and ID3; other similarities are noted in the figure.
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Extended Data Fig. 8 | SigProfiler signature extraction and attribution.  
A full description is provided in Supplementary Note 2. a, Procedure for 
extracting (discovering) mutational signatures. Step A, apply the approach to a 
set of samples D; initially D contains all samples (that is, D = M). This step has 
previously been described in detail17. Step B, solution evaluation and re-
iteration. Extracted mutational signatures and their activities in individual 
samples are saved into a set (S). The activity of any signature that does not 
increase the cosine similarity of a sample by > 0.01 was removed from the 
sample (assigned a value of 0). Step A is repeated for all samples for which the 
identified signatures do not explain their patterns (cosine similarity < 0.95). 
The algorithm continues to step C when step A cannot find any stable 
signatures. Step C, clustering of mutational signatures. Hierarchical consensus 
clustering was applied to the set S to derive the consensus mutational 
signatures across the set of samples M. b, Attribution of activities of mutational 
signatures in samples.
Extended Data Table 1 | The number of DBSs is proportional to the number of SBSs, with few exceptions
The exceptions are colorectal adenocarcinoma (Colorect–AdenoCA), lung adenocarcinoma (Lung–AdenoCA), lung squamous cell carcinoma (Lung–SCC) and skin–melanoma, as analysed by 
the following linear regression (computed by an R function call): glm(DBS.count ~ SBS.count + Cancer.Type). This function call fits a model in which the number of DBSs depends linearly on the 
number of SBSs and on the cancer type. P values associated with the coefficients are two-sided.
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Extended Data Table 2 | Numbers of insertion and deletion mutations due to ID1, ID2 and all other indel signatures in 
hypermuted and non-hypermutated tumours
1nature research  |  reporting sum
m
ary
O
ctober 2018
Corresponding author(s): Steven G. Rozen and Michael R. Stratton
Last updated by author(s): Oct 8, 2019
Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection The data in this study were those reported in https://www.biorxiv.org/content/early/2017/07/12/162784.full.pdf+html (the PCAWG 
marker paper) and in the publications cited at  https://www.synapse.org/#!Synapse:syn11801788.  
 
For the larger PCAWG Consortium, data and metadata were collected from International Cancer Genome Consortium (ICGC) consortium 
members using custom software packages designed by the ICGC Data Coordinating Centre. The general-purpose core libraries and 
utilities underlying this software have been released under the GPLv3 open source license as the "Overture" package and are available at 
https://www.overture.bio. Other data collection software used in this effort, such as ICGC-specific portal user interfaces, are available 
upon request to contact@overture.bio. 
Data analysis SigProfiler is available both as a MATLAB framework and as a Python package. In both cases, SigProfiler is fully functional, free, and open-
source tool distributed under the permissive 2-Clause BSD License. SigProfiler in MATLAB can be downloaded from: https://
www.mathworks.com/matlabcentral/fileexchange/38724-sigprofiler SigProfiler in Python can be downloaded from: https://github.com/
AlexandrovLab/SigProfilerExtractor. SignatureAnalyzer code is available at https://www.synapse.org/#!Synapse:syn11801492. The code 
used to generate the synthetic data and summarize SignatureAnalyzer and SigProfiler results is open-source and freely available as the 
SynSig package: https://github.com/steverozen/ SynSig/tree/v0.2.0 under the GPL3 license.  
 
For the larger PCAWG Consortium, the workflows executing core WGS alignment, QC and variant-calling software are packaged as 
executable Dockstore images and available at: https://dockstore.org/search?labels.value.keyword=pcawg&searchMode=files. Individual 
software components are as follows: BWA-MEM v0.78.8-r455; DELLY v0.6.6; ACEseq v1.0.189; DKFZ somatic SNV workflow v1.0.132-1; 
Platypus v0.7.4; ascatNgs v1.5.2; BRASS v4.012; grass v1.1.6; CaVEMan v1.50; Pindel v1.5.7; ABSOLUTE/JaBbA v1.5; SvABA 2015-05-20; 
dRanger 2016-03-13; BreakPointer 2015-12-22; MuTect v1.1.4; MuSE v1.0rc; SMuFIN 2014-10-26; OxoG 2016-4-28; VAGrENT v2.1.2; 
ANNOVAR v2014Nov12; VariantBAM v2017Dec12; SNV-Merge v2017May26; SV-MERGE v2017Dec12; DKFZ v2016Dec15
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
2nature research  |  reporting sum
m
ary
O
ctober 2018
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Derived data are available at https://www.synapse.org/#!Synapse:syn11726601/wiki/513478. All figures and extended data figures have associated raw data at that 
site.   
 
For the larger PCAWG Consortium, WGS somatic and germline variant calls, mutational signatures, subclonal reconstructions, transcript abundance, splice calls and 
other core data generated by the ICGC/TCGA Pan-cancer Analysis of Whole Genomes Consortium are available for download at https://dcc.icgc.org/releases/
PCAWG. Additional information on accessing the data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In accordance with the data 
access policies of the ICGC and TCGA projects, most molecular, clinical and specimen data are in an open tier which does not require access approval. To access 
potentially identification information, such as germline alleles and underlying sequencing data, researchers will need to apply to the TCGA Data Access Committee 
(DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, and to the ICGC Data Access Compliance 
Office (DACO; http://icgc.org/daco) for the ICGC portion. In addition, to access somatic single nucleotide variants derived from TCGA donors, researchers will also 
need to obtain dbGaP authorization.
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size From a statistical perspective this was an exploratory study, and there were no pre-defined hypothesis tests for which sample-size power 
calculations would have been appropriate.  The sample size was determined by numbers of tumour genomes and exomes represented by 
publicly available somatic mutation data. These data consisted of the ICGC Pan Cancer whole genome mutation data, the TCGA MC3 whole 
exome mutation data, and additional mutation data as described in https://www.synapse.org/#!Synapse:syn11801788.  This was an 
unsupervised analysis, and therefore we extracted as many signatures as possible from all the available data. This enabled a substantial 
increment over previously available sets of mutational signatures, especially with respect to double base substitution (DBS) signatures and 
insertion/deletion (ID) signatures.  
 
For the larger PCAWG Consortium,  the Consortium compiled an inventory of matched tumour/normal whole cancer genomes in the ICGC 
Data Coordinating Centre. Most samples came from treatment-naïve, primary cancers, but there were a small number of donors with multiple 
samples of primary, metastatic and/or recurrent tumours. Our inclusion criteria were: (i) matched tumour and normal specimen pair; (ii) a 
minimal set of clinical fields; and (iii) characterisation of tumour and normal whole genomes using Illumina HiSeq paired-end sequencing 
reads.  
We collected genome data from 2,834 donors, representing all ICGC and TCGA donors that met these criteria at the time of the final data 
freeze in autumn 2014. 
Data exclusions From a statistical perspective this was an exploratory study, and there were no pre-defined hypothesis tests for which pre-defined data 
exclusion criteria would have been appropriate. Therefore, no data were excluded from analysis by our algorithms. 
 
For the larger PCAWG Consortium,  after quality assurance, data from 176 donors were excluded as unusable. Reasons for data exclusions 
included inadequate coverage, extreme bias in coverage across the genome, evidence for contamination in samples and excessive sequencing 
errors (for example, through 8-oxoguanine).
Replication This was not an experimental study, and there were no experimental replicates. 
 
For the larger PCAWG Consortium, in order to evaluate the performance of each of the mutation-calling pipelines and determine an 
integration strategy, we performed a large-scale deep sequencing validation experiment. We selected a pilot set of 63 representative tumour/
normal pairs, on which we ran the three core pipelines, together with a set of 10 additional somatic variant-calling pipelines contributed by 
members of the SNV Calling Working Group. Overall, the sensitivity and precision of the consensus somatic variant calls were 95% (CI90%: 
88-98%) and 95% (CI90%: 71-99%) respectively for SNVs. For somatic indels, sensitivity and precision were 60% (34-72%) and 91% (73-96%) 
respectively. Regarding SVs, we estimate the sensitivity of the merging algorithm to be 90% for true calls generated by any one caller; 
precision was estimated as 97.5% - that is, 97.5% of SVs in the merged SV call-set have an associated copy number change or balanced 
partner rearrangement.
Randomization There were no experimental groups in this study; the question of allocation to experimental groups is not applicable. 
 
For the larger PCAWG Consortium, no randomisation was performed.
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Blinding There was no allocation to experimental groups; the question of whether investigators were blinded to allocation is not applicable. 
 
For larger PCAWG Consortium, no blinding was undertaken.
Behavioural & social sciences study design
All studies must disclose on these points even when the disclosure is negative.
Study description Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, 
quantitative experimental, mixed-methods case study). 
Research sample State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information 
(e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving 
existing datasets, please describe the dataset and source.
Sampling strategy Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to 
predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale 
for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria 
were used to decide that no further sampling was needed.
Data collection Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, 
computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether 
the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale 
behind them, indicating whether exclusion criteria were pre-established.
Non-participation State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no 
participants dropped out/declined participation.
Randomization If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if 
allocation was not random, describe how covariates were controlled.
Ecological, evolutionary & environmental sciences study design
All studies must disclose on these points even when the disclosure is negative.
Study description Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, 
hierarchical), nature and number of experimental units and replicates.
Research sample Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National 
Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and 
any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, 
describe the data and its source.
Sampling strategy Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size 
calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for 
these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which 
the data are taken
Data exclusions If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, 
indicating whether exclusion criteria were pre-established.
Reproducibility Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to 
repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were 
controlled. If this is not relevant to your study, explain why.
Blinding Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why 
blinding was not relevant to your study.
Did the study involve field work? Yes No
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Field work, collection and transport
Field conditions Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
Location State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water 
depth).
Access and import/export Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and 
in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing 
authority, the date of issue, and any identifying information).
Disturbance Describe any disturbance caused by the study and how it was minimized.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used Describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone name, and lot number.
Validation Describe the validation of each primary antibody for the species and application, noting any validation statements on the 
manufacturer’s website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) State the source of each cell line used.
Authentication Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.
Mycoplasma contamination Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for 
mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.
Palaeontology
Specimen provenance Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the 
issuing authority, the date of issue, and any identifying information).
Specimen deposition Indicate where the specimens have been deposited to permit free access by other researchers.
Dating methods If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), 
where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new 
dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
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Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.
Wild animals Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals 
were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if 
released, say where and when) OR state that the study did not involve wild animals.
Field-collected samples For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, 
photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
Ethics oversight Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or 
guidance was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics For the PCAWG Consortium data, patient-by-patient clinical data are provided in the marker paper for the PCAWG consortium 
(Extended Data Table 1 of that manuscript). Demographically, the cohort included 1,469 males (55%) and 1,189 females (45%), 
with a mean age of 56 years (range, 1-90 years). Using population ancestry-differentiated single nucleotide polymorphisms 
(SNPs), the ancestry distribution was heavily weighted towards donors of European descent (77% of total) followed by East 
Asians (16%), as expected for large contributions from European, North American and Australian projects. We consolidated 
histopathology descriptions of the tumour samples, using the ICD-0-3 tumour site controlled vocabulary. Overall, the PCAWG 
data set comprises 38 distinct tumour types. While the most common tumour types are included in the dataset, their 
distribution does not match the relative population incidences, largely due to differences among contributing ICGC/TCGA groups 
in numbers sequenced.  The non-PCAWG analyses used previously published data.
Recruitment For the PCAWG Consortium data, patients were recruited by the participating centres following local protocols. 
Ethics oversight For the PCAWG Consortium data, the Ethics oversight for the PCAWG protocol was undertaken by the TCGA Program Office and 
the Ethics and Governance Committee of the ICGC. Each individual ICGC and TCGA project that contributed data to PCAWG had 
their own local arrangements for ethics oversight and regulatory alignment.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Study protocol Note where the full trial protocol can be accessed OR if not available, explain why.
Data collection Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Outcomes Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.
ChIP-seq
Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links 
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links.  For your "Final submission" document, 
provide a link to the deposited data.
Files in database submission Provide a list of all files available in the database submission.
Genome browser session 
(e.g. UCSC)
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to 
enable peer review.  Write "no longer applicable" for "Final submission" documents.
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Methodology
Replicates Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of 
reads and whether they were paired- or single-end.
Antibodies Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone 
name, and lot number.
Peak calling parameters Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and 
index files used.
Data quality Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold 
enrichment.
Software Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a 
community repository, provide accession details.
Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
Instrument Identify the instrument used for data collection, specifying make and model number.
Software Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a 
community repository, provide accession details.
Cell population abundance Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples 
and how it was determined.
Gating strategy Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell 
population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance imaging
Experimental design
Design type Indicate task or resting state; event-related or block design.
Design specifications Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial 
or block (if trials are blocked) and interval between trials.
Behavioral performance measures State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used 
to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across 
subjects).
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Acquisition
Imaging type(s) Specify: functional, structural, diffusion, perfusion.
Field strength Specify in Tesla
Sequence & imaging parameters Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, 
slice thickness, orientation and TE/TR/flip angle.
Area of acquisition State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
Diffusion MRI Used Not used
Preprocessing
Preprocessing software Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, 
segmentation, smoothing kernel size, etc.).
Normalization If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types 
used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.
Normalization template Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. 
original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
Noise and artifact removal Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and 
physiological signals (heart rate, respiration).
Volume censoring Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.
Statistical modeling & inference
Model type and settings Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first 
and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).
Effect(s) tested Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether 
ANOVA or factorial designs were used.
Specify type of analysis: Whole brain ROI-based Both
Statistic type for inference
(See Eklund et al. 2016)
Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Correction Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte 
Carlo).
Models & analysis
n/a Involved in the study
Functional and/or effective connectivity
Graph analysis
Multivariate modeling or predictive analysis
Functional and/or effective connectivity Report the measures of dependence used and the model details (e.g. Pearson correlation, partial 
correlation, mutual information).
Graph analysis Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, 
subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, 
etc.).
Multivariate modeling and predictive analysis Specify independent variables, features extraction and dimension reduction, model, training and evaluation 
metrics.
